Cyclophosphamide

During or immediately after cyclophosphamide for injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity. Malignant Diseases: Adult and Pediatric Patients Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Hypersensitivity Cyclophosphamide for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur. Urinary Outflow Obstruction Cyclophosphamide for injection is contraindicated in patients with urinary outflow obstruction. Hypersensitivity to cyclophosphamide Urinary outflow obstruction

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections: Severe immunosuppression may lead to serious and sometimes fatal infections. Close hematological monitoring is required. Urinary Tract and Renal Toxicity: Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur. Urotoxicity can be fatal. Exclude or correct any urinary tract obstructions prior to treatment. Cardiotoxicity: Myocarditis, myopericarditis, pericardial effusion, arrythmias and congestive heart failure, which may be fatal, have been reported.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following adverse reactions are discussed in more detail in other sections of the labeling. Hypersensitivity Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections Urinary Tract and Renal Toxicity Cardiotoxicity Pulmonary Toxicity Secondary Malignancies Veno-occlusive Liver Disease Infertility Impaired Wound Healing Hyponatremia Adverse reactions reported most often include neutropenia, febrile…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

57 products from 25 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 57 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store vials at or below 25°C (77°F). Storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide.

Storage information from the U.S. FDA-approved label.